PMID- 32284620
OWN - NLM
STAT- MEDLINE
DCOM- 20210426
LR  - 20210426
IS  - 1804-7521 (Electronic)
IS  - 1213-8118 (Linking)
VI  - 164
IP  - 2
DP  - 2020 Jun
TI  - Gene rearrangement detection by next-generation sequencing in patients with 
      non-small cell lung carcinoma.
PG  - 127-132
LID - 10.5507/bp.2020.015 [doi]
AB  - Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related 
      deaths worldwide. Various molecular markers in NSCLC patients have been 
      developed, including gene rearrangements, currently used in therapeutic 
      strategies. With increasing number of these molecular biomarkers of NSCLC, there 
      is a demand for highly efficient methods for detecting mutations and 
      translocations in treatable targets. Those currently available U.S. Food and Drug 
      Administration (FDA) approved approaches, for example imunohistochemisty (IHC) 
      and fluorescence in situ hybridization (FISH), are inadequate, due to sufficient 
      quantity of material and long time duration. Next-generation massive parallel 
      sequencing (NGS), with the ability to perform and capture data from millions of 
      sequencing reactions simultaneously could resolve the problem. Thanks to gradual 
      NGS introduction into clinical laboratories, screening time should be 
      considerably shorter, which is very important for patients with advanced NSCLC. 
      Moreover, only a minimum sample input is needed for achieving adequate results. 
      NGS was compared to the current detection methods of ALK, ROS1, c-RET and c-MET 
      rearrangements in NSCLC and a significant match, between IHC, FISH and NGS 
      results, was found. Recent available researches have been carried out on a small 
      numbers of patients. Verifying these results on larger patients cohort is 
      important. This review sumarizes the literature on this subject and compares 
      current possibilities of predictive gene rearrangements detection in patients 
      with NSCLC.
FAU - Brisudova, Aneta
AU  - Brisudova A
AD  - Department of Clinical and Molecular Pathology, Faculty of Medicine and 
      Dentistry, Palacky University Olomouc, Czech Republic.
FAU - Skarda, Jozef
AU  - Skarda J
AD  - Department of Clinical and Molecular Pathology, Faculty of Medicine and 
      Dentistry, Palacky University Olomouc, Czech Republic.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200406
PL  - Czech Republic
TA  - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
JT  - Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, 
      Czechoslovakia
JID - 101140142
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (MET protein, human)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret)
RN  - EC 2.7.10.1 (RET protein, human)
RN  - EC 2.7.10.1 (ROS1 protein, human)
SB  - IM
MH  - Anaplastic Lymphoma Kinase/genetics
MH  - Carcinoma, Non-Small-Cell Lung/diagnosis/*genetics
MH  - Gene Rearrangement/genetics
MH  - High-Throughput Nucleotide Sequencing/*methods
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/diagnosis/*genetics
MH  - Molecular Targeted Therapy
MH  - Mutation/genetics
MH  - Oncogene Fusion/*genetics
MH  - Protein-Tyrosine Kinases/genetics
MH  - Proto-Oncogene Proteins/genetics
MH  - Proto-Oncogene Proteins c-met/genetics
MH  - Proto-Oncogene Proteins c-ret/genetics
MH  - Sequence Analysis, DNA
MH  - Sequence Analysis, RNA
MH  - Translocation, Genetic/genetics
OTO - NOTNLM
OT  - fluorescence in situ hybridization
OT  - gene rearrangement
OT  - immunohistochemistry
OT  - next-generation sequencing
OT  - non-small cel lung carcinoma
EDAT- 2020/04/15 06:00
MHDA- 2021/04/27 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/11/11 00:00 [received]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/04/27 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - 10.5507/bp.2020.015 [doi]
PST - ppublish
SO  - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Jun;164(2):127-132. 
      doi: 10.5507/bp.2020.015. Epub 2020 Apr 6.